Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Articles
-
COVID-19: We all have skin in the game
Blueberry Therapeutics is a drug development company committed to finding new and improved treatments for a range of dermatological conditions affecting the skin and nails. The future and long-term effect of the global COVID-19 pandemic (caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2 virus]) on dermatology practice and skin health is still unknown, but here we provide some ...
-
Ozette’s AI in the battle against Covid - Case study
Summary The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began in 2019 and rapidly scaled to a global presence of disease known as COVID-19. Despite the relatively fast implementation of testing and vaccination worldwide, the rise of emerging viral variants and breakthrough infections raises concerns that SARS-CoV-2 will continue to pose a global health threat. ...
-
Evaluation of the Talis One Covid-19 Test System for the Rapid Detection of Sars-Cov-2 and Emerging Variants
Introduction The discovery of a novel coronavirus in December 2019 in the Wuhan province of China and subsequent global spread has caused a pandemic of the scale not seen since the 1918 H1N1 pandemic. The novel coronavirus, classified as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly infectious and causes coronavirus disease 2019 (COVID-19), a respiratory and vascular ...
-
Quantitative Assessment of Viral Dispersion Associated with Respiratory Support Devices in a Simulated Critical Care Environmen
Abstract Rationale:Patients with severe coronavirus disease (COVID-19) require supplemental oxygen and ventilatory support. It is unclear whether some respiratory support devices may increase the dispersion of infectious bioaerosols and thereby place healthcare workers at increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objectives:To ...
By Inspir Labs
-
Mysterious Deltacron, a Hybrid of Delta and Omicron?
On January 8, 2022, Bloomberg reported that Leondios Kostrikis, a professor of biological sciences at the University of Cyprus, and his team had discovered a new variant of SARS-CoV-2, named "Deltacron" because it has an Omicron-like genetic signature in the Delta genome. Deltacron, according to Kostrikis, mixes genes from Delta and Omicron and may have come from patients who had both Delta and ...
-
Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
Abstract Messenger RNA (mRNA) based vaccines (Pfizer/BioNTech and Moderna) are highly effective at providing immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is uncertainty about the duration of immunity, evolution of IgG antibody levels and IgG avidity (an index of antibody-antigen binding strength), and differences in the immune responses between ...
-
COVID-19 Disease Testing; Utilising Fluorescence During a Pandemic
While the world continues to endure loss and hardship due to the outbreak of COVID-19, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers are scrambling to provide test kits that are accurate, fast, sensitive, and widely available, especially as symptoms vary broadly and may not appear for days if at all. To this end, several diagnostic methods have been ...
-
Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2
The recent COVID-19 pandemic again highlighted the urgent need for broad-spectrum antivirals, both for therapeutic use in acute viral infection and for pandemic preparedness in general. The targeting of host cell factors hijacked by viruses during their replication cycle presents one possible strategy for development of broad-spectrum antivirals. By inhibiting the Raf/MEK/ERK signaling pathway, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you